DexCom (NASDAQ:DXCM) Stock Price Up 4.8%

DexCom, Inc. (NASDAQ:DXCM) shares rose 4.8% during mid-day trading on Tuesday . The stock traded as high as $70.74 and last traded at $70.71. Approximately 1,482,503 shares changed hands during trading, a decline of 56% from the average daily volume of 3,370,121 shares. The stock had previously closed at $67.48.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective on the stock. UBS Group cut their target price on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Morgan Stanley cut their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $111.50.

DexCom Price Performance

The company has a market capitalization of $27.97 billion, a price-to-earnings ratio of 43.54, a price-to-earnings-growth ratio of 1.58 and a beta of 1.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The business has a fifty day moving average price of $114.02 and a 200 day moving average price of $123.33.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period last year, the company earned $0.34 earnings per share. On average, research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold a total of 3,483 shares of company stock valued at $401,450 over the last three months. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after purchasing an additional 136,282 shares in the last quarter. Capital Research Global Investors boosted its position in DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the period. Sands Capital Management LLC boosted its position in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after acquiring an additional 1,398,136 shares during the period. Capital World Investors boosted its position in DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership boosted its position in DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after acquiring an additional 3,672,471 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.